2. 2 in 3 children Globally, with retinoblastoma die For $440 per child
we will make retinoblastoma a zero death cancer
and test a novel approach to health optimization

3. Retinoblastoma (RB) RB is cancer of the infant retina
8,000 RB cases annually worldwide with 70% mortality
Complex care, large multidisciplinary teams, with poor communication
No standard of care, doctor opinion selects treatment, uniquely failed evidence base
Patient families have limited access to medical records

4. DEPICT HEALTH
DEPICT HEALTH will index, and collect lifelong data from, every child diagnosed with retinoblastoma globally
For each patient, DEPICT HEALTH will enhance communication across the circle of care, independent of geography
Globally, data collated by DEPICT HEALTH will empower research, including machine learning, that will improve outcomes and ultimately eliminate deaths
Retinoblastoma is a realistic pilot of this novel approach to healthcare optimization given that it is a rare neglected disease with public demand for evidence

5. FULL VIEW FOR LIFE

6. DEPICT HEALTH Enhances Communication Across the Circle of Care
Family controls view-only access
Lifelong data entry
Circle of Care becomes a TEAM
FAMILY controls view only access

7. Enhanced Communication Incentivizes Point-of-Care DEPICT HEALTH Data Entry

9. DEPICT HEALTH Will Be Deployed Using An Existing Network of RB Treatment Centres
India and china
Different social models

10. DEPICT HEALTH Governance
Patients Participate
Coded Data
Research
Steering Committee
Direct
Operations Committee
Advise
Working Groups
Support
oversight
Sites
circle of care
Communicate by
DEPICT HEALTH
Machine Learning
REAL WORLD evidence

11. DEPICT HEALTH Deploy DEPICT HEALTH
$4.4 million to onboard 180 treatment centers
Deploy DEPICT HEALTH
$8.0 million to create and support 52,000 patient accounts
Maintain DEPICT HEALTH
$6.7 million for research, including machine learning
Develop RB Evidence Base

12. Username: demo-user Password: Demo1234
DEPICT HEALTH
Username: demo-user Password: Demo1234
On Internet cloud
Secure standards
Fully identified
Coded data for research
cT2bN0M0H1*
Group A
cT1a
Group D
cT2b
cT2bN0M0H1*
Group A
cT1a
Group D
cT2b
cT2bN0M0H1*
Group A
cT1a
Group D
cT2b
cT2bN0M0H1*
Group A
cT1a
Group D
cT2b
cT2bN0M0H1*
Group A
cT1a
Group D
cT2b
cT2bN0M0H1*
Group A
cT1a
Group D
cT2b
cT2bN0M0H1*
Group A
cT1a
Group D
cT2b
cT2bN0M0H1*
Group A
cT1a
Group D
cT2b
Dimaras H, Corson TW, Cobrinik D, et al. Retinoblastoma. Nature Reviews Disease Primers. 2015:15021.
*Mallipatna A, Gallie BL, Chévez-Barrios P, et al. Retinoblastoma. In: Amin MB, Edge SB, Greene FL, eds.
AJCC Cancer Staging Manual. Vol 8th Edition. New York, NY: Springer; 2017:

13. Retinoblastoma will be a zero death cancer
Brenda Gallie, MD
The International Retinoblastoma Consortium
Toronto Canada